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An excess of interleukin 17 (IL-17) may contribute to chronic inﬂammatory disorders, but mecha-
nisms that regulate IL-17 in immune cells are unclear. Here we report that tristetraprolin (TTP)
inhibits IL-17 production in human T cell lines. Overexpression of TTP decreased the expression
of IL-17. Conversely, TTP inhibition by siRNA increased IL-17 production. IL-17 mRNA contains eight
AREs within its 30UTR. TTP bound directly to the IL-17 mRNA 30UTR at a location between the fourth
and seventh AREs and enhanced decay of IL-17 transcripts. These results suggest that TTP could con-
trol IL-17-mediated inﬂammation.
 2011 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Interleukin-17 (IL-17) is a regulatory cytokine involved in the
innate immune response against extracellular bacteria and fungi
[1]. However, IL-17 also participates in the pathogenesis of inﬂam-
matory disease [2]. IL-17 is secreted by TH17 cells, macrophages,
dendritic cells, natural killer cells, and cd-T cells [1]. In vitro, a com-
bination of IL-6 and TGF-b induces IL-17 production, which IL-23
then stabilizes [3]. IL-17 levels increase signiﬁcantly in chronic
inﬂammatory diseases [2], while the use of IL-17-blocking antibod-
ies may prevent development of those diseases or diminish their
severity [4]. IL-17-blocking antibodies are currently in clinical tri-
als for this use [5].
Many inﬂammatory cytokine and chemokine mRNAs are known
to be unstable [6]. Their expression is modulated by post-
transcriptional control, which is strongly dependent on AU-rich
element (ARE)-mediated mechanisms [7]. The AREs may destabi-
lize the inﬂammatory signaling mRNAs through speciﬁc binding
to proteins that promote mRNA degradation [8]. Tristetraprolin
(TTP) is one ARE-binding protein involved in inﬂammatoryon behalf of the Federation of Euro
o), jwpark@uou.ulsan.ac.kr,
y to this work.
es, Dong-A University, Busancytokine regulation [9]. TTP-knockout mice develop severe inﬂam-
matory arthritis and autoimmune dysfunction, which supports the
role of TTP in limiting the inﬂammatory response [10].
In the present study, we investigated the role of TTP in human T
cells and found that TTP overexpression decreased IL-17 produc-
tion. On the other hand, TTP inhibition by siRNA increased IL-17
content in the cells. IL-17mRNA contains several AREs in the 30UTR
by which TTP may promote its decay. Our results show that IL-17
mRNA is a physiological target of TTP and suggest that TTP may
play a key role in preventing IL-17-mediated inﬂammatory dis-
eases through the destabilization of IL-17 transcripts.
2. Materials and methods
2.1. Cells
The human T cell lines, HuT 102 and Jurkat, were maintained in
RPMI 1640 medium and Dulbecco’s modiﬁed Eagle’s medium,
respectively. All cell lines were supplemented with 10% FBS
(HyClone) at 37 C in a humidiﬁed atmosphere of 5% CO2. The
HuT 102 cells were stimulated with medium alone or with immo-
bilized anti-CD3 and anti-CD28 Abs for 24 h and 48 h. Ab stimula-
tions were performed by culturing cells in culture dishes that had
been coated at 4 C overnight with a suspension containing 1 lg/
ml anti-human CD3 mAb (R&D System) and 2 lg/ml anti-human
CD28 mAb (R&D System) in PBS.pean Biochemical Societies.
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IL-17 in the cell supernatants was analyzed using the Human IL-
17A ELISA Ready-SET-Go! system according to the manufacturer’s
instructions (eBioscience).
2.3. Plasmids and siRNAs
The pcDNA6/V5-TTP construct has been described previously
[11]. Full-length and deletion mutants of the human IL-17 30UTR
was PCR-ampliﬁed from the cDNA of HuT 102 cells using Taq poly-
merase (SunGenetics, Korea) and a set of primers (Table 1). Four
oligonucleotides containing AUUUA motifs (ARE-1-2, ARE-3-7,
ARE-4-7, and ARE-8) of the IL-17 30UTR were synthesized at Inte-
grated DNA Technologies (IDT) (Table 1). Mutant ARE-4-7 oligonu-
cleotides in which AUUUA pentamers were substituted with AGCA
were also synthesized. PCR products and the oligonucleotides were
inserted into the XhoI/NotI sites of a psiCHECK2 Renilla/ﬁreﬂy dual-
luciferase expression vector (Promega).
Small interfering RNAs (siRNAs) against human TTP (TTP-siRNA)
(sc-36761) and control siRNA (scRNA) (sc-37007) were purchased
from Santa Cruz Biotechnology.
2.4. Transfections and luciferase assay
Cells (5 x106)were transfectedwithplasmid constructs and siRNAs
by electroporation at 1400 V for 30 ms using the Neon™ Transfection
System (Invitrogen) according to the manufacturer’s instructions.
Lysates of the transfected cells were mixed with luciferase assay
reagent (Promega), and chemiluminescence was measured in a
Wallac Victor 1420 Multilabel Counter (EG&G Wallac). Renilla
luciferase activity of the psiCHECK2/IL-17 30UTR was normalized
to ﬁreﬂy luciferase in each sample.
2.5. Electrophoretic mobility shift assay (EMSA)
The biotinylated RNA probes for wild-type (Oligo-ARE-4-7,
50-CCUGUAUUUAUUUGAGCUAUUUAAGGAUCUAUUUAUGUUUAA-
GUAUUUAGAAAA-30) and mutant (Oligo-ARE-4-7/m4-7, 50-CCUG-
UAGCAUUUGAGCUAGCAAGGAUCUAGCAUGUUUAAGUAGCAGAAAA-
30) were synthesized by Samchully Pharm. Co., Ltd. (Korea). ATable 1
PCR primers and Oligonucleotides used in this study.
Name (forward and reverse) Sequences (50 ? 30)
Full-ARE CCGCTCGAGGAGCTCTGGGGAGCCCACACT, ATAAGAA
Frag-DARE-1-2 TAAGGGCTTTAAGTTATATGCCCTGAGATAACT, AGTTA
Frag-DARE-3-7 GGCTTGGGAATTTTATTGAAAAAGGTGAAAAAGCAC, G
Frag-DARE-8 CTACTTTCATATGTATTAAATTTTGCAATTTGTTG, CAAC
Oligo-ARE-1/2 CGAGTTTAAGGGCTTTAAGTTATTTATGTATTTAATATG
GGCCGCCCCAAAGTTATCTCAGGGCATATTAAATACATA
Oligo-ARE-3-7 TCGAGCTTGGGAATTTTATTATTTAAAAGGTAAAACCTG
GGCCGCTCACCTTTTTCTAAATACTTAAACATAAATAGA
Oligo-ARE-4-7 TCGAGACCTGTATTTATTTGAGCTATTTAAGGATCTATT
GGCCGCTTTCTAAATACTTAAACATAAATAGATCCTTAA
Oligo-ARE-8 TCGAGGATTAAACCTACTTTCATATGTATTAATTTAAAT
GGCCGCCTTGTAAAACCTCAACAAATTGCAAAATTTAAA
Oligo-ARE-4-7(4 m) TCGAGACCTGTAGCATTTGAGCTATTTAAGGATCTATTT
GGCCGCTTTCTAAATACTTAAACATAAATAGATCCTTAA
Oligo-ARE-4-7(5 m) TCGAGACCTGTATTTATTTGAGCTAGCAAGGATCTATTT
GGCCGCTTTCTAAATACTTAAACATAAATAGATCCTTGC
Oligo-ARE-4-7(6 m) TCGAGACCTGTATTTATTTGAGCTATTTAAGGATCTAGC
GGCCGCTTTCTAAATACTTAAACATGCTAGATCCTTAAA
Oligo-ARE-4-7(7 m) TCGAGACCTGTATTTATTTGAGCTATTTAAGGATCTATT
GGCCGCTTTCTGCTACTTAAACATAAATAGATCCTTAAA
Oligo-ARE-4-7(all m) TCGAGACCTGTAGCATTTGAGCTAGCAAGGATCTAGCA
GGCCGCTTTCTGCTACTTAAACATGCTAGATCCTTGCTA
Underlined sequences, wild-type and mutant AREs.
Mutations (bold characters) were introduced to the AREs in the Oligo-ARE-4-7.mutant RNA probe in which four AUUUA pentamers were each
substituted with AGCA was used as a negative control. Cytoplasmic
extracts were prepared from HuT 102 cells using NE-PER Nuclear
and Cytoplasmic Extraction Reagent (Thermo Pierce Biotechnology
Scientiﬁc). RNA EMSAwas performed using the Lightshift Chemol-
uminescent EMSA Kit (Thermo Pierce Biotechnology Scientiﬁc)
according to the manufacturer’s instructions. For the supershift
EMSA, anti-TTP antibody (ab36558, Abcam) or control antibody
(I-5381, Sigma) was added to the reaction mixture.
2.6. SDS–PAGE analysis and immunoblotting
Proteins were resolved by SDS–PAGE, transferred to Hybond-P
membranes (GE Healthcare Bio-Sciences Corp.), and probed with
the appropriate dilution of anti-V5 antibody (20-783-70389, Gen-
Way). Immunoreactivity was detected using the ECL detection sys-
tem (GE Healthcare Bio-Sciences Corp.).
2.7. Quantitative real-time PCR
For RNA kinetic analysis, we used actinomycinD and assessed IL-
17mRNA expression by quantitative real-time PCR (qRT-PCR) using
the ABI Prism 7900 HT to monitor the increase in SYBR Green dye
ﬂuorescence over time (QIAGEN). PCR primer pairs were as follows:
qIL-17: ACTACAACCGATCCACCTCAC, ACTTTGCCTCCCAGATCACAG;
qGAPDH: ATCTTCAAGCCATCCTGTGTGC, TGCGCTTGTCACATTTTTC-
TTG. TTP mRNA expression was determined by qRT-PCR using PCR
primers: qTTP: ACTACAACCGATCCACCTCAC, ACTTTGCCTCCCAGA-
TCACAG.
2.8. Statistics
For statistical comparisons, P values were determined using
Student’s t-test.
3. Results
3.1. TTP down-regulates the IL-17 expression in human T cell lines
Analysis of the 1346 bp human IL-17 mRNA 30UTR revealed the
presence of eight ARE motifs (Fig. 3A). To determine the effect ofTGCGGCCGCGGGCGAAAATGGTTACGATGTG.
TCTCAGGGCATATAACTTAAAGCCCTTA
TGCTTTTTCACCTTTTTCAATAAAATTCCCAAGCCC
AAATTGCAAAATTTAATACATATGAAAGTAG
CCCTGAGATAACTTTGGGGC,
AATAACTTAAAGCCCTTAAAC
TATTTATTTTGAGCTATTTAAGGATCTATTTATGTTTAAGTATTTAGAAAAAGGTGAGC,
TCCTTAAATAGCTCAAATAAATACAGGTTTTACCTTTTAAATAATAAAATTCCCAAGC
TATGTTTAAGTATTTAGAAAGC,
ATAGCTCAAATAAATACAGGTC
TTTGCAATTTGTTGAGGTTTTACAAGGC,
TTAATACATATGAAAGTAGGTTTAATCC
ATGTTTAAGTATTTAGAAAGC,
ATAGCTCAAATGCTACAGGTC
ATGTTTAAGTATTTAGAAAGC,
TAGCTCAAATAAATACAGGTC
ATGTTTAAGTATTTAGAAAGC,
TAGCTCAAATAAATACAGGTC
TATGTTTAAGTAGCAGAAAGC,
TAGCTCAAATAAATACAGGTC
TGTTTAAGTAGCAGAAAGC,
GCTCAAATGCTACAGGTC
H.H. Lee et al. / FEBS Letters 586 (2012) 41–46 43TTP on IL-17 expression, we transiently transfected HuT 102 cells
with pcDNA6/V5-TTP (HuT 102/TTP). As a negative control, HuT
102 cells were transfected with an empty pcDNA6/V5 vector (HuT
102/pcDNA). Overexpression of TTP in HuT 102 cells was conﬁrmed
byWestern blots (Fig. 1A). In a parallel experiment, IL-17 expression
was analyzed in HuT 102 cells transfected with pcDNA6/V5-TTP
(HuT 102/TTP) and pcDNA6/V5 (HuT 102/pcDNA) using ELISA
(Fig. 1B) and quantitative real-time PCR (qRT-PCR) (Fig. 1C). TTP
overexpression signiﬁcantly reduced IL-17 expression (Fig. 1B and C).
To test the effect of TTP down-regulation on IL-17 expression,
we treated Jurkat cells with TTP-speciﬁc siRNA. This treatment sig-
niﬁcantly decreased TTP level (Fig. 1D and F) but increased IL-17
expression (Fig. 1D and E), while treatment with non-speciﬁc siR-
NA (scRNA) did not affect endogenous expression of either TTP or
IL-17. Collectively, these results indicate that TTP down-regulates
IL-17 expression in human T cells.
3.2. TTP destabilizes IL-17 mRNA
Wemeasured the half-life of IL-17mRNA in HuT 102 cells trans-
fected with pcDNA6/V5-TTP or the empty pcDNA6/V5 vector byA
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2 h after actinomycin D treatment in empty vector-transfected
cells (HuT 102/pcDNA), the half-life was signiﬁcantly reduced to
less than 2 h in TTP-transfected cells (HuT 102/TTP) (Fig. 2). This
shows that TTP overexpression decreases IL-17 expression through
destabilization of IL-17 mRNA.3.3. TTP overexpression decreases the expression of luciferase mRNA
containing the IL-17 30UTR
Wewished to conﬁrm that the IL-17 30UTR is required for TTP to
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30UTR Full). When HuT 102 cells were transfected to overexpress
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pared to that of HuT 102 cells transfected with pcDNA6/V5
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Fig. 3. AREs within the IL-17 mRNA 30UTR are essential for the inhibitory effect of TTP. (
White circles represent the wild-type (w) ARE motif, AUUUA, and black circles represent
reporter containing the IL-17 30UTR. The HuT 102 cells were cotransfected with luciferase
V5-TTP. Renilla luciferase activity was normalized to ﬁreﬂy activity. The luciferase values
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pcDNA6/V5. Results shown on the graph represent the mean ± S.D. of three independen
44 H.H. Lee et al. / FEBS Letters 586 (2012) 41–463.4. An ARE cluster (ARE 4-7) within the IL-1730UTR is involved in TTP-
mediated mRNA destabilization
To identify AREs within the IL-17 30UTR that are required for
TTP activity, we linked luciferase reporter genes to various dele-
tion and point mutant constructs of the IL-17 30UTR (Fig. 3A).
While TTP decreased the luciferase activity of the reporter gene
cloned upstream of IL-17 30UTR Full (containing all eight AREs)
by 68%, less reporter gene inhibition was observed for Frag-
DARE-1/2 (containing ARE3ARE8, 64%), Frag-DARE-8 (contain-
ing ARE1ARE7, 51%), and Frag-DARE-3-7 (containing ARE1,
ARE2, and ARE8, 33%) (Fig. 3C). These results showed that the
IL-17 30UTR region containing ARE3ARE7 is required for TTP
to down-regulate IL-17.
To conﬁrm that the regulatory effect of TTP requires ARE3-
ARE7, we prepared the following oligonucleotide fragments of
the IL-17 30UTR region: Oligo-ARE-1-2 (containing ARE1 and
ARE2), Oligo-ARE-3-7 (containing ARE3ARE7), Oligo-ARE-4-7A) Schematic representation of the luciferase reporter constructs used in this study.
the mutated (m) motif, AGCA. (B) Inhibition by TTP overexpression of the luciferase
reporters containing the full-length IL-17 30UTR (IL-17 30UTR Full) and with pcDNA/
obtained from cells cotransfected with the luciferase construct and pcDNA6/V5 were
periments (⁄P < 0.05). (C) Mapping of the sequence in IL-17mRNA 30UTR required for
luciferase reporter construct as described in (A), and with pcDNA6/V5-TTP. After
ith each construct was compared to inhibition obtained with the empty vector,
t experiments (⁄P < 0.05; ⁄⁄P < 0.01).
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Fig. 4. TTP binds directly to AREs within the IL-17 mRNA 30UTR. An RNA EMSA was
performed by mixing cytoplasmic extracts containing 4 lg of total protein from
HuT 102 cells with 10 fmol of biotinylated wild-type (Oligo-ARE-4-7) or mutant
(Oligo-ARE-4-7/m4-7) probe. Anti-TTP and control antibody were added to the
reaction mixtures. Arrows indicate the position of the TTP-containing band.
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(Fig. 3A). While TTP inhibited Oligo-ARE-3-7 and Oligo-ARE-4-7
by 47% and 42% inhibition, respectively, Oligo-ARE-1-2 and Oli-
go-ARE-8 resisted the destabilizing effect of TTP (26% and 25% inhi-
bition, respectively) (Fig. 3C). To identify the ARE motif(s) most
critically involved in the response to TTP, we prepared fourTTP
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control, we also prepared one quadruple-mutant (Oligo-ARE-4-7/
m4-7) in which all four AUUUA motifs were substituted with
AGCA. The quadruple-mutant Oligo-ARE-4-7/m4-7 did not respond
to TTP. However, no single ARE mutation affected the response to
TTP (Fig. 3C). Thus, a cluster of ARE-4-7 within the IL-17 30UTR
was required for TTP to destabilize the IL-17 mRNA.
3.5. TTP binds to the ARE cluster (ARE 4-7) within the IL-17 mRNA
30UTR
To determine whether TTP interacts directly with ARE-4-7 of
the IL-17 30UTR, we performed an RNA EMSA using a biotinylated
RNA probe containing the wild-type or mutant ARE-4-7 UTR. This
RNA probe was identical to the oligonucleotide (Oligo-ARE-4-7)
used for the luciferase assay. A quadruple-mutant Oligo-ARE-4-7/
m4-7 was used as a negative control. In cytoplasmic extracts of
HuT 102 cells, RNA EMSA analysis revealed an RNA-binding protein
for the wild-type probe but not for the mutant probe (Fig. 4). This
RNA-protein complex was reduced by preincubation of the reac-
tion mixture with an anti-TTP antibody. Thus, TTP interacted
directly with the Oligo-ARE-4-7 containing the ARE cluster (ARE-
4-7) in the IL-17 mRNA 30UTR.
3.6. Stimulation of HuT 102 cells increases TTP level but decreases IL-
17 level
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lyzed the level of TTP and IL-17 in HuT 102 cells at 24 h and 48 h
after stimulation with anti-CD3 and anti-CD28 Abs. Consistent
with the previous report, stimulation of HuT 102 cells induced
increased expression of TTP at 24 h and 48 h (Fig. 5A and B). How-
ever, there was no change in the level of IL-17 at 24 h after stimu-
lation. At later time after stimulation, at 48 h, the IL-17 level was
decreased (Fig. 5C and D). This result suggests that stimulation of
HuT 102 cells induces TTP expression but decreases IL-17 level at
48 h after stimulation.4. Discussion
The cytokine IL-17 is a prominent mediator of inﬂammation
and inﬂammatory disease [1]. Until now, the mechanism for IL-
17 down-regulation was unclear. Here we demonstrate that TTP
suppresses IL-17 expression in the human T cells. We found that
TTP promoted IL-17 mRNA degradation through binding to a clus-
ter of ARE motifs within the IL-17 30UTR. Our deletion and muta-
tion analysis showed that the region containing ARE4 through
ARE7 is essential for the response to TTP.
Evidence shows that TTP enhances the decay of ARE-containing
cytokine genes such as tumor necrosis factor-a (TNF-a) [9], granu-
locyte-macrophage colony stimulating factor (GM-CSF) [14], IL-10
[15], IL-2 [13] and IL-23 [16] and that TTP-mediated decay of ARE-
containing cytokine mRNAs exerts control over an inﬂammatory
response [9,10]. TTP-deﬁcient mice develop a systemic inﬂamma-
tory syndrome caused by cytokine overproduction [9,10]. Strong
inﬂammatory stimuli such as LPS activate p38 MAPK, which in turn
deactivates control by TTP [17]. In this situation, a change in p38
MAPK signaling is required to restore post-transcriptional control
of IL-17 expression.
Elevated expression of TTP has been reported in T cell receptor-
stimulated T cells [12,13]. Consistent with this, we found that
stimulation of HuT 102 cells with anti-CD3/anti-CD28 for 24 h
increased TTP level. However, interestingly, we observed that
stimulation of HuT 102 cells for 24 h did not decrease IL-17 level.
This coincides with previous report that stimulation of HuT 102
cells does not affect IL-17 production [18]. It is unclear why TTP
induced at 24 h did not down-regulate the IL-17 level. One possi-
bility is that p38 MAPK activated by TcR stimulation [19] phos-
phorylates TTP and inhibits its activity [17]. At later time after
stimulation, IL-17 level was decreased, indicating the change in
p38 MAPK signaling pathway leading to restoration of TTP activity.
It has been shown that TGF-b is produced by activated T cells [20]
and that it inhibits p38 MAPK and enhances the mRNA-destabiliz-
ing activity of TTP [21]. Thus one may hypothesize that TGF-b
produced at later time of stimulation inhibits p38 MAPK activity
and leads to TTP activation. Further study is required to determine
whether TGF-b inﬂuences the destabilizing effect of TTP on IL-17
mRNA.
In conclusion, this studyconﬁrmedthat IL-17 containsAREmotifs
within its 30UTR, and that TTP destabilizes IL-17 mRNA by direct
binding to an ARE cluster containing ARE4 through ARE7. Because
IL-17 over-expression may contribute to chronic inﬂammatory dis-
ease, the inhibitionof IL-17productionby enhancingTTP expression
and activity may have important clinical implications.Acknowledgments
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